Innate Immune Stimulating Therapies - Virtual Summit

Memo

The inaugural Innate Immune Stimulating Therapies Summit has arrived with a dedicated focus on achieving safe and effective clinical and commercial translation of STING and TLR therapies. Join the leaders in the field, from key biotech, large pharma, and academia, to discuss how to optimize the administration of innate immune stimulating therapies from IT delivery through to antibody conjugated approaches. If you are looking to make long lasting connections with industry leaders and take part in discussions about the lessons learned on the journey to translating safe and effective innate immune stimulating therapies for patients in need, then this is the meeting for you. Earlybird discounts are available so book now for the best possible rate. Academic and group discounts also apply. Visit the website to learn more. URLs:Tickets: https://go.evvnt.com/599444-2?pid=5569 Brochure: https://go.evvnt.com/599444-3?pid=5569  Time: 08:30 to 18:00 Prices:Conference Ticket (1st Release): USD 1199.00,Conference Ticket (2nd Release): USD 1299.00,Conference Ticket (3rd Release): USD 1399.00,Conference Ticket (Final Release): USD 1499.00 Speakers: Kimberly Schluns, Associate Professor, University of Texas MD Anderson Cancer Center, Saul Kivimae, Head of In Vivo Pharmacology, Nektar Therapeutics, Xingfeng Bao, Senior Director, Immuno-Oncology, H3biomedicine, Arthur Krieg, Chief Scientific Officer, Checkmate Pharmaceuticals, Valerie Odegard, Chief Scientific Officer, Silverback Therapeutics, Marc Damelin, Executive Director and Head of Biology, Mersana Therapeutics Inc., Michael Alonso, Vice President, Immunology and Pharmacology, Bolt Biotherapeutics, Kristy Ainslie, Professor and Vice Chair, Eshelman School of Pharmacy University of North Carolina, Shahram Ardakani, Senior Director, Pfizer, Haifeng Yang, Co-Director of Translational Pathology Shared Resource, Sidney Kimmel Cancer Center, Sarah McWhirter, Executive Director - Research and Translational Medicine, Aduro Biotech, Diwakar Davar, Assistant Professor - Melanoma and Phase I Therapeutics, UPMC, Christopher Matheny, Director of Clinical Development - Oncology R and D, GSK, Christopher Thanos, Cofounder and Chief Executive Office, Actym Therapeutics, Michael J. Newman, Founder and Chief Executive Officer, Decoy Biosystems, Ming Li Member, Immunology Program, Memorial Sloan Kettering Cancer Center, Adi Diab, Assistant Professor, University of Texas - MD Anderson Cancer Center, Tom Dubensky, Chief Executive Officer, Tempest Therapeutics, Lijun Sun, Director of Biology, Immune Sensor Therapeutics